Rapid Antibody and Antigen Testing Kit Market Definition
Rapid antibody and antigen testing kit are used for diagnosing any kind of respiratory bacteria and diseases associated with it, these tests detect the specific viral infection giving quick results. The antigen testa is done on the nasal swab and antibody tests are done to detect the antibodies developing in the body through the immune system in response to the active infection. The rapid antibody and antigen testing kit are used in hospitals, clinics, diagnostics laboratories, and even at home care settings. The kit consists of testing material like strips /tests per box, 1x test cassette, 1x desiccant pouch, 25x disposable pipettes, sample diluent along with guiding instruction for the testing. With the help of these components, serum, plasma, or whole blood sample is taken for the testing showing results in 10-15 minutes.
The market study is broken down and major geographies with country level splits.
Abbott Laboratories (United States), Thermo Fisher Scientific (United States), BioMedomics, Inc. (United States), SD Biosensor, Inc. (South Korea), Oxford Biomedica (United Kingdom), BioLab Sciences (United States), CTK Biotech, Inc. (United States), Roche Holding AG (Switzerland), R-Biopharm AG (Germany) and Celltrion (South Korea) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Rapid Antibody and Antigen Testing Kit market by Type, Application and Region.
On the basis of geography, the market of Rapid Antibody and Antigen Testing Kit has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Components, the sub-segment i.e. 50 Strips /Tests Per Box will boost the Rapid Antibody and Antigen Testing Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disease, the sub-segment i.e. Autoimmune Diseases will boost the Rapid Antibody and Antigen Testing Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sample, the sub-segment i.e. Serum will boost the Rapid Antibody and Antigen Testing Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals will boost the Rapid Antibody and Antigen Testing Kit market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategies
On 8th April 2020, BioLab Sciences, a regenerative biotechnology company, announced they are now distributing tests to detect antibodies specific to 2019n-CoV in humans. The test devices complete the screening using a blood sample from a finger prick and produce results in 10 minutes. and On 12th March 2020, CTK Biotech, Inc. launched Test kits for COVID-19. CTK collaborated with its partners in China, and launched two diagnostic tests for this virus, both a real-time PCR based nucleic acid detection kit and a serological rapid screening test, for the International market.
On 26th August 2020, Abbott announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its BinaxNOW COVID-19 Ag Card rapid test for detection of COVID-19 infection. Abbott will sell this test for a 5US Dollar,15-minute, easy-to-use COVID-19 antigen test receives FDA emergency use authorization; mobile app displays test results to help our return to daily life; ramping production to 50 million tests a month. and On 1st September 2020, Roche announced that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the CE Mark. Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S. Food and Drug Administration (FDA).
"The U.S. Food and Drug Administration has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. The EUA was issued to Quidel Corporation for the Sofia 2 SARS Antigen FIA. This test is authorized for use in high and moderate complexity laboratories certified by Clinical Laboratory Improvement Amendments (CLIA), as well as for point-of-care testing by facilities operating under a CLIA Certificate of Waiver."
- Continuous Research and Development in the Antibody and Antigen Testing
- Increasing Number of COVID-19 Cases in Various Region of the World
- Need for the Rapid Diagnostics Kits for Faster Treatment
- Emerging New Kinds of Deadly Diseases
- Surging Government Intervention and Investment to Diagnose Any Kind of Autoimmune Disease will Boost the Rapid Antibody and Antigen Testing Kit Market
- Less Skilled Professional for the Rapid Antibody and Antigen Testing Kit Operation
- Low-Quality False Result Showing Rapid Antibody and Antigen Testing Kit Players in the Market
Key Target Audience
Rapid Antibody and Antigen Testing Kit Manufacturers, Rapid Antibody and Antigen Testing Kit Distributors and Suppliers, Hospital Industry Association, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase